Zacks: Brokerages Expect Soligenix, Inc. (SNGX) Will Announce Earnings of -$0.32 Per Share
Equities analysts expect Soligenix, Inc. (NASDAQ:SNGX) to announce earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Soligenix’s earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.22). Soligenix posted earnings of ($0.17) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 88.2%. The business is expected to issue its next quarterly earnings results on Monday, March 26th.
According to Zacks, analysts expect that Soligenix will report full-year earnings of ($1.20) per share for the current year, with EPS estimates ranging from ($1.30) to ($1.10). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.40) per share, with EPS estimates ranging from ($2.00) to ($0.80). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Soligenix.
Soligenix (NASDAQ:SNGX) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.15. Soligenix had a negative return on equity of 112.81% and a negative net margin of 90.93%. The firm had revenue of $1.82 million during the quarter, compared to analyst estimates of $1.36 million.
Shares of Soligenix (NASDAQ SNGX) opened at $2.16 on Friday. Soligenix has a 1-year low of $1.74 and a 1-year high of $5.08. The firm has a market capitalization of $19.21 and a P/E ratio of -2.08.
In related news, insider Spa Essetifin bought 293,510 shares of Soligenix stock in a transaction that occurred on Wednesday, November 29th. The stock was purchased at an average cost of $2.12 per share, for a total transaction of $622,241.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.03% of the stock is currently owned by insiders.
Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.